Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 12, 2019 (7 years ago)

IRINOTECAN 250 MG /500 ml D5W IVPB

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

IRINOTECAN 250 MG /500 ml D5W IVPB; IRINOTECAN 110 MG /250 ML D5W IVPB; IIRINOTECAN 250 MG/250 ML NS IVPB; IRINOTECAN 315 MG / 250 ML NS IVPB; IRINOTECAN 155 MG / 500 ml D5W IVPB; IRINOTECAN 75 MG / 250 ML NS IVPB; IRINOTECAN 140 MG / 250 ML NS IVPB; IRINOTECAN 317 MG /500 ML D5W IVPB; IRINOTECAN 135 mg / 500 ml D5W IVPB; IRINOTECAN 265 MG / 500 ML D5W IVPB; IRINOTECAN 140 MG / 500 ml D5W IVPB; IRINOTECAN 195 mg / 500 ml D5W IVPB; IRINOTECAN 245 mg / 500 ml D5W IVPB; IRINOTECAN 130 MG / 500 ML D5W IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233

Drug: Irinotecan

Recalling firm
Infusion Options, Inc.
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1787-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Irinotecan recalls

See all
Class II · Moderate risk

Irinotecan Hydrochloride Injection

CGMP Deviations: based on a Warning Letter received by the manufacturer of the recalled product for inadequate out-of specification investigations, complaint and the investigation conclusions.

Terminated Failed specification Areva Pharmaceuticals Inc NDC 59923-714-02 D-0270-2021
Class II · Moderate risk

Irinotecan HCL Injection

Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

Terminated Packaging defect Hikma Pharmaceuticals USA Inc. NDC 0143-9583-01 D-1309-2020
Class II · Moderate risk

Irinotecan HCL Injection

Defective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.

Terminated Packaging defect Hikma Pharmaceuticals USA Inc. NDC 0143-9701-01 D-1308-2020

Other recalls by Infusion Options, Inc.

All 2019 recalls